This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Sharewise Webinar With CEO Dr Daniel Tillett
In this webinar hosted by Sharewise, Race Oncology CEO Dr Daniel Tillet presents the company’s current journey in the drug development process.
Dr. Tillett covers bisantrene’s potential for global cancer patients, its unique ability to deliver both anti-cancer and cardioprotection, and its current stage of clinical development. He also answers a range of questions from investors.
You can watch the full Sharewise webinar here.